The company's cTA® pathology platform integrates wet assay and image analysis to provide drug developers with advanced technology and scientific strategy to accelerate drug approval. Flagship's biomarker analysis improves on traditional methods by eliminating variability and providing new insights. The company offers expert scientific consultation to interpret results and identify the best course for success.